ClinicalTrials.gg

Program

NOA LIFT

Its studies are led by AbbVie.

Furthest: phase 3, since Aug 27, 20261 company-led study, 1 open or runningNext primary completion: Aug 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AbbVie11 open or runningphase 3since Aug 27, 2026Aug 27, 2026Aug 2028phase 3 · NCT07794878

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 27, 2026First study: phase 3 study in Nasolabial FoldsFirst studyNCT07794878 · 288 planned · China

Ahead

  1. Aug 2028Primary completion: phase 3 study in Nasolabial FoldsNCT07794878

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07794878Nasolabial Folds · China3RecruitingAug 2028288

How it is read

Names in the registry

  • “NOA LIFT”, 1 entry

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.